Treatment of primary HIV-1 infection with HAART may represent a unique opportunity to alter the course of this chronic disease. In spite of this, enthusiasm for the "hit early, hit hard" approach has waned over time, given the lack of data showing long-term clinical benefit. This article will examine the risks and benefits of starting HAART during acute HIV-1 disease.
|Original language||English (US)|
|State||Published - May 1 2005|
- Acute HIV infection
- Antiretroviral therapy
- Primary HIV-1 infection
ASJC Scopus subject areas
- Infectious Diseases